BR112021024176A2 - Anticorpos anti-angpt2 - Google Patents
Anticorpos anti-angpt2Info
- Publication number
- BR112021024176A2 BR112021024176A2 BR112021024176A BR112021024176A BR112021024176A2 BR 112021024176 A2 BR112021024176 A2 BR 112021024176A2 BR 112021024176 A BR112021024176 A BR 112021024176A BR 112021024176 A BR112021024176 A BR 112021024176A BR 112021024176 A2 BR112021024176 A2 BR 112021024176A2
- Authority
- BR
- Brazil
- Prior art keywords
- angpt2
- antibodies
- angpt2 antibodies
- angiopoietin
- therapeutic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
anticorpos anti-angpt2. a presente invenção se refere a anticorpos neutralizantes anti-angiopoietina 2 (angpt2) para métodos terapêuticos e de diagnóstico e composição que os utiliza.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962867253P | 2019-06-27 | 2019-06-27 | |
US202063013022P | 2020-04-21 | 2020-04-21 | |
PCT/US2020/039477 WO2020264065A1 (en) | 2019-06-27 | 2020-06-25 | Anti-angpt2 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021024176A2 true BR112021024176A2 (pt) | 2022-03-22 |
Family
ID=71662321
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021024176A BR112021024176A2 (pt) | 2019-06-27 | 2020-06-25 | Anticorpos anti-angpt2 |
Country Status (19)
Country | Link |
---|---|
US (2) | US11396539B2 (pt) |
EP (1) | EP3990489A1 (pt) |
JP (1) | JP2022538062A (pt) |
KR (1) | KR20220028032A (pt) |
CN (1) | CN114080396B (pt) |
AU (1) | AU2020308569A1 (pt) |
BR (1) | BR112021024176A2 (pt) |
CA (1) | CA3140071A1 (pt) |
CL (1) | CL2021003367A1 (pt) |
CO (1) | CO2021017414A2 (pt) |
CR (1) | CR20210683A (pt) |
EC (1) | ECSP22004680A (pt) |
IL (1) | IL289160A (pt) |
JO (1) | JOP20210339A1 (pt) |
MA (1) | MA56394A (pt) |
MX (1) | MX2021015743A (pt) |
PE (1) | PE20220809A1 (pt) |
TW (1) | TW202115112A (pt) |
WO (1) | WO2020264065A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202115112A (zh) * | 2019-06-27 | 2021-04-16 | 德商百靈佳殷格翰國際股份有限公司 | 抗-angpt2抗體 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE266710C (pt) | ||||
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4434173A (en) | 1982-08-23 | 1984-02-28 | Pfizer Inc. | Bis-esters of 4,5-di(hydroxymethyl)-2-oxo-1,3-dioxole as antibacterial agents |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
ATE196606T1 (de) | 1992-11-13 | 2000-10-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
US6455035B1 (en) * | 1999-03-26 | 2002-09-24 | Regeneron Pharmaceuticals, Inc. | Angiopoietins and methods of use thereof |
KR101017301B1 (ko) * | 2004-12-21 | 2011-02-28 | 메드임뮨 리미티드 | 앤지오포이에틴-2에 대한 항체 및 그의 용도 |
US8133979B2 (en) * | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
US20110227286A1 (en) * | 2010-03-18 | 2011-09-22 | Davies Janet L | Board Game and Method of Playing the Same |
US9575073B2 (en) * | 2011-10-10 | 2017-02-21 | Rutgers, The State University Of New Jersey | Detection of high-risk intraductal papillary mucinous neoplasm and pancreatic adenocarcinoma |
EP2822594A4 (en) | 2012-03-08 | 2016-02-17 | Medimmune Llc | METHODS OF TREATMENT WITH ANTI-ANGIOPOIETIN-2 ANTIBODIES |
EP3381940B1 (en) | 2013-07-29 | 2022-09-07 | Samsung Electronics Co., Ltd. | Anti-ang2 antibody |
WO2015091655A1 (en) | 2013-12-20 | 2015-06-25 | F. Hoffmann-La Roche Ag | Combination therapy with an anti-ang2 antibody and a cd40 agonist |
AR100270A1 (es) * | 2014-05-19 | 2016-09-21 | Lilly Co Eli | Anticuerpos ang2 |
HUE053239T2 (hu) * | 2014-11-19 | 2021-06-28 | Axon Neuroscience Se | Humanizált tau-ellenanyagok Alzheimer-kór kezelésére |
JP2020503843A (ja) * | 2016-10-21 | 2020-02-06 | アディマブ, エルエルシー | 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法 |
CR20210381A (es) * | 2017-09-29 | 2021-09-09 | Chugai Pharmaceutical Co Ltd | MOLÉCULA DE UNIÓN AL ANTÍGENO MULTIESPECÍFICA QUE TIENE ACTIVIDAD DE SUSTITUCIÓN DE LA FUNCIÓN DE COFACTOR DEL FACTOR VIII DE COAGULACIÓN DE SANGRE (FVIII) Y FORMULACIÓN FARMACÉUTICA QUE CONTIENE TAL MOLÉCULA COMO INGREDIENTE (Divisional Exp. 2020-0158) |
TW202115112A (zh) * | 2019-06-27 | 2021-04-16 | 德商百靈佳殷格翰國際股份有限公司 | 抗-angpt2抗體 |
-
2020
- 2020-06-24 TW TW109121573A patent/TW202115112A/zh unknown
- 2020-06-25 JP JP2021576151A patent/JP2022538062A/ja active Pending
- 2020-06-25 PE PE2021002220A patent/PE20220809A1/es unknown
- 2020-06-25 BR BR112021024176A patent/BR112021024176A2/pt unknown
- 2020-06-25 CN CN202080047312.1A patent/CN114080396B/zh active Active
- 2020-06-25 CA CA3140071A patent/CA3140071A1/en active Pending
- 2020-06-25 US US16/911,419 patent/US11396539B2/en active Active
- 2020-06-25 WO PCT/US2020/039477 patent/WO2020264065A1/en active Application Filing
- 2020-06-25 EP EP20742550.5A patent/EP3990489A1/en active Pending
- 2020-06-25 KR KR1020227003085A patent/KR20220028032A/ko unknown
- 2020-06-25 JO JOP/2021/0339A patent/JOP20210339A1/ar unknown
- 2020-06-25 AU AU2020308569A patent/AU2020308569A1/en active Pending
- 2020-06-25 MX MX2021015743A patent/MX2021015743A/es unknown
- 2020-06-25 CR CR20210683A patent/CR20210683A/es unknown
- 2020-06-25 MA MA056394A patent/MA56394A/fr unknown
-
2021
- 2021-12-16 CL CL2021003367A patent/CL2021003367A1/es unknown
- 2021-12-17 CO CONC2021/0017414A patent/CO2021017414A2/es unknown
- 2021-12-20 IL IL289160A patent/IL289160A/en unknown
-
2022
- 2022-01-19 EC ECSENADI20224680A patent/ECSP22004680A/es unknown
- 2022-06-17 US US17/842,904 patent/US20220363743A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2021015743A (es) | 2022-01-27 |
KR20220028032A (ko) | 2022-03-08 |
WO2020264065A1 (en) | 2020-12-30 |
CR20210683A (es) | 2022-02-23 |
IL289160A (en) | 2022-02-01 |
TW202115112A (zh) | 2021-04-16 |
AU2020308569A1 (en) | 2021-12-02 |
CL2021003367A1 (es) | 2022-10-07 |
US11396539B2 (en) | 2022-07-26 |
EP3990489A1 (en) | 2022-05-04 |
CN114080396A (zh) | 2022-02-22 |
CN114080396B (zh) | 2024-05-17 |
MA56394A (fr) | 2022-05-04 |
US20220363743A1 (en) | 2022-11-17 |
JP2022538062A (ja) | 2022-08-31 |
CA3140071A1 (en) | 2020-12-30 |
PE20220809A1 (es) | 2022-05-20 |
JOP20210339A1 (ar) | 2023-01-30 |
CO2021017414A2 (es) | 2022-01-17 |
ECSP22004680A (es) | 2022-02-25 |
US20200407435A1 (en) | 2020-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021001706A1 (es) | Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos (divisional de solicitud no. 201900326) | |
CL2020001048A1 (es) | Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281) | |
BR112021021736A2 (pt) | Batente de tecido para um instrumento cirúrgico | |
BR112017023943A2 (pt) | anticorpos heterodimêricos que ligam cd3 e antígenos de tumor | |
AR109625A1 (es) | Proteínas de unión a antígenos (abp) que se unen selectivamente a tigit y métodos para el uso de las mismas | |
BR112016025009A2 (pt) | anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície | |
BR112016030670A2 (pt) | "imunocitoquina" | |
UY37594A (es) | Biomarcador inmunologico para predecir el efecto clinico de inmunoterapia del cancer | |
CL2023002048A1 (es) | Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos | |
BR112019023990A2 (pt) | Bis-octa-hidrofenantreno carboxamidas e conjugados de proteína das mesmas | |
UY30525A1 (es) | Agentes de union dirigidos cuyo blanco es el pdgfr-alfa y sus usos | |
CL2021002331A1 (es) | Formulaciones de anticuerpo anti-il-36r | |
BR112021024956A2 (pt) | Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3 | |
ECSP21052193A (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r | |
BR112022003956A2 (pt) | Anticorpos anti-cd73 | |
BR112021011729A2 (pt) | Tubulisinas e conjugados de proteína-tubulisina | |
BR112019010128A2 (pt) | proteínas de ligação a antígeno anti-gitr e métodos de uso das mesmas | |
CO2020014343A2 (es) | Anticuerpos específicos para cd3 y sus usos | |
CO2023017156A2 (es) | Anticuerpos anti-sirp-alfa | |
CO2023006684A2 (es) | Anticuerpos contra sars-cov-2 y usos de los mismos | |
CL2021001607A1 (es) | Anticuerpos anti-pmel17 y conjugados de los mismos | |
BR112015031950A2 (pt) | métodos para tratamento de câncer de ovário | |
CO2023002375A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
CL2021002866A1 (es) | Tratamiento de la cefalea usando anticuerpos anti-cgrp. | |
BR112021024176A2 (pt) | Anticorpos anti-angpt2 |